Bio-Rad Laboratories, Inc. (BIO-B)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 03:59PM EDT
| Previous close | 332.20 |
| Open | 337.45 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 800 |
| Day's range | 338.55 - 338.55 |
| 52-week range | 271.00 - 467.95 |
| Volume | |
| Avg. volume | 267 |
| Market cap | 8.538B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Bio-Rad Laboratories (NYSE:BIO shareholders incur further losses as stock declines 14% this week, taking three-year losses to 53%
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Bio-Rad Laboratories...
- Zacks
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
- GuruFocus.com
OncoCyte Corp (OCX) Q4 2023 Earnings Call Transcript Highlights: Strategic Partnerships and ...
OncoCyte details reduced burn rate, Bio-Rad partnership, and growth in the transplant market, alongside a significant net loss in Q4 2023.
© 2024 Yahoo. All rights reserved.